Innovent Biologics (HKSE:01801) Construction In Progress: HK$506 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01801 Innovent Biologics Inc HKSE:01801
84 GF Score
Price HK$92.15
GF Value HK$100.93
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Construction In Progress?

Innovent Biologics HKSE:01801 +3.60% 84 Construction In Progress is HK$506 Mil as of Dec. 2025. GuruFocus rates HKSE:01801 with a GF Score™ of 84/100 and a GF Value™ of HK$100.93 (Fairly Valued). The stock has 2 warning signs investors should review.

Innovent Biologics's quarterly construction in progress declined from Dec. 2024 (HK$1,587 Mil) to Jun. 2025 (HK$62 Mil) but then increased from Jun. 2025 (HK$62 Mil) to Dec. 2025 (HK$506 Mil).

Innovent Biologics's annual construction in progress declined from Dec. 2023 (HK$2,557 Mil) to Dec. 2024 (HK$1,587 Mil) and declined from Dec. 2024 (HK$1,587 Mil) to Dec. 2025 (HK$506 Mil).

Innovent Biologics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Innovent Biologics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Construction In Progress Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,933.51 1,533.59 2,557.26 1,586.52 506.09

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,557.26 0.00 1,586.52 61.89 506.09
HKSE:01801
84GF Score
Innovent Biologics Inc HKSE:01801
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovent Biologics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$506 Mil mean?
Innovent Biologics (HKSE:01801) has a Construction In Progress of HK$506 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' Construction In Progress too high?
Innovent Biologics' current Construction In Progress is HK$506 Mil. Overall, Innovent Biologics has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Construction In Progress compare to VRTX and REGN?
Innovent Biologics' Construction In Progress of HK$506 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Construction In Progress is HK$506 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (HKSE:01801) is currently considered Fairly Valued. The stock's GF Value™ is HK$100.93, compared to a current price of HK$92.15 — trading 8.7% below its estimated fair value. The current Construction In Progress is HK$506 Mil. Innovent Biologics' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Innovent Biologics (HKSE:01801), the current Construction In Progress is HK$506 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (HKSE:01801) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of HK$92.15 is trading 8.7% below its estimated GF Value™ of HK$100.93. GuruFocus considers Innovent Biologics to be Fairly Valued.

Key valuation signals for HKSE:01801:

  • Construction In Progress: HK$506 Mil
  • GF Value™: HK$100.93 vs. price of HK$92.15 (8.7% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
84GF Score

Get the complete analysis for HKSE:01801

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$92.15
Price
HK$100.93
GF Value